Our Blog
See below for an opinion on current matters around the world.
Raising the Bar: How the 2024 Access to Medicine Index Shapes the Pharmaceutical Industry’s ESG Agenda
The Good, the Bad, and the Ugly: Australia’s HTA Review Final Report
Is the new price right?: HTA takes a back seat to broader price negotiations
Christmas Santa or Christmas Scrooge?: England's new medicines pricing regime sends mixed messages
Land of the Long Wait Crowd: problems in New Zealand's medicine funding system
Have health and the PBS come of age as the Intergenerational Report turns 21?
Pharmaceuticals Take Centre Stage in Australian Election Campaign
Australians now understand there is a 'queue' for new health technologies
NICE methods review, UK Life Sciences Strategy and the life sciences industry: lessons for Australia
Fair dinkum or collywobbles? Life sciences and the Australia – UK free trade agreement
More risk for government this time around in agreement negotiation
It's just the vibe: soft skills in the art of government-business relations
5 Trends for Life Science Companies to Watch in 2021
The next 20-year PBS agenda: government commitments to new medicines spending
PBS New Medicines Funding Guarantee: echoes of elections past ...